Pediatric Studies Of Difficult-To-Treat Cancers To Get Advisory Cmte. Review
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline's Votrient (pazopanib), Genentech's vismodegib and two investigational drugs will be the subjects for the Pediatric Oncology Subcommittee of FDA's Oncologic Drugs Advisory Committee Nov. 1.